Corteva, Inc. · CTVA · FY2026 Q3 · Calendar Q4 2026

Corteva Q3: New Products Grow as Brazil Weakness Cuts Outlook

Corteva's differentiated products and pipeline are contributing to growth outside Brazil, but the quarter's sharp Brazil deterioration and lower full-year EBITDA outlook make execution and recovery in that market central to the outlook.

Why did CTVA fall 19.6% after beating EPS estimates in FY2026 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported After market closeNYSEBasic Materials $8.08B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.06 Consensus $0.02
EPS surprise +231.9% Reported versus consensus
Reported revenue $1.59B Consensus $1.77B
Revenue surprise -10.4% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

event-close to next-session close
Stock move -19.6% Event window
SPY move -0.3% Same window
Abnormal move -19.3% Stock minus SPY
Volume 2.2× Versus trailing sessions
Subsequent drift 0.0% Up to 20 sessions
CTVASPY benchmark

Ask FN2 about CTVA FY2026 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

In its first earnings call as a standalone company, Corteva reported 20% growth in new-product volumes, while Brazil organic sales fell 31% amid economic stress, currency impacts, weather and excess inventory. Management lowered full-year EBITDA guidance and announced the company's first standalone quarterly dividend.

Guidance delta

Full-year operating EBITDA guidance was lowered to $1.1 billion–$1.125 billion. The supplied analysis does not provide the prior standalone guidance range for a direct comparison.

Key takeaways

  • New-product volumes grew 20%, supporting growth outside Brazil.
  • Brazil's 31% organic sales decline was the principal pressure highlighted in the supplied analysis.
  • Year-to-date operating EBITDA was flat despite $230 million of pricing headwinds; margins improved slightly.
  • Management outlined a multi-quarter cost-transformation program and continued R&D investment.

Management priorities

  • Normalize Brazil channel inventory and rebuild profitability in that market.
  • Implement cost transformation focused on process simplification and technology adoption over the next 4–8 quarters.
  • Continue R&D and pipeline launches through 2027–2028, while maintaining disciplined SG&A spending.

Follow CTVA with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
CTVA EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q2 '24 estimate $1.73 Q2 '24 actual $1.83, beat Q3 '24 estimate $-0.30 Q3 '24 actual $-0.49, miss Q2 '25 estimate $1.89 Q2 '25 actual $2.20, beat Q3 '25 estimate $-0.51 Q3 '25 actual $-0.23, beat Q4 '25 estimate $0.22 Q4 '25 actual $0.22, match Q1 '26 estimate $1.17 Q1 '26 actual $1.50, beat Q2 '26 estimate $2.24 Q2 '26 actual $2.30, beat Q3 '26 estimate $0.09 Q3 '26 actual $-0.04, miss Q4 '26 estimate $0.27 Q1 '27 estimate $1.47
Show 2 more >

Analyst Consensus ?

ConsensusBuy36 ratings
Bullish2466.7%
Neutral1027.8%
Bearish25.5%

Analyst 52W Price Targets

$7.89Current
$11Low
$60.86Average
$101High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
UBS Neutral NeutralMaintainOct 12, 2026
Keybanc Overweight Sector WeightUpgradeOct 7, 2026
JP Morgan Overweight NeutralUpgradeOct 6, 2026
Argus Research Buy BuyMaintainSep 18, 2026
Citigroup Neutral NeutralMaintainSep 17, 2026
RBC Capital Outperform OutperformMaintainSep 16, 2026
BMO Capital Outperform OutperformMaintainSep 16, 2026
Oppenheimer Outperform OutperformMaintainJul 23, 2026
B of A Securities Buy BuyMaintainJul 20, 2026
Mizuho Outperform OutperformMaintainJul 14, 2026
Barclays Overweight OverweightMaintainJun 11, 2026
Morgan Stanley Overweight OverweightMaintainMay 28, 2026
Wells Fargo Overweight OverweightMaintainApr 21, 2026
Jefferies Buy BuyMaintainJun 6, 2025
Deutsche Bank Buy BuyMaintainJun 12, 2024
OTR Global Negative MixedDowngradeJun 7, 2024
Canaccord Genuity Buy BuyMaintainMay 3, 2024
Loop Capital Buy HoldUpgradeFeb 12, 2024
Exane BNP Paribas Neutral UnderperformUpgradeFeb 2, 2024
Roth MKM Buy BuyMaintainJan 29, 2024
Berenberg Hold BuyDowngradeNov 27, 2023
Fermium Research Outperform OutperformMaintainOct 30, 2023
Goldman Sachs Neutral NeutralMaintainOct 24, 2023
Credit Suisse Outperform OutperformMaintainAug 4, 2023
Redburn Partners Neutral BuyDowngradeJul 25, 2023
Vertical Research Buy HoldUpgradeMay 22, 2023
Roth Capital Buy BuyMaintainOct 8, 2021
Monness, Crespi, Hardt Neutral SellUpgradeAug 9, 2021
Redburn Neutral BuyDowngradeJan 21, 2021
Susquehanna Positive NeutralUpgradeMar 31, 2020
Edward Jones Buy HoldUpgradeMar 19, 2020
Bernstein Outperform Market PerformUpgradeJan 23, 2020
SunTrust Robinson Humphrey Hold HoldMaintainOct 11, 2019
Citi Buy NeutralUpgradeAug 19, 2019
Monness Crespi Hardt Sell SellMaintainJul 17, 2019
Nomura Neutral NeutralMaintainJun 10, 2019
Show less

Named analyst price targets

Upside is calculated against the persisted current price $7.89. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Mizuho SecuritiesJohn Roberts$13$9.43 +64.8%Nov 16, 2026
RBC CapitalArun Viswanathan$11$9.33 +39.4%Nov 13, 2026
Mizuho SecuritiesJohn Roberts$16$12.11 +102.8%Nov 12, 2026
UBSAnalyst unavailable$15$12.91 +90.1%Oct 12, 2026
Goldman SachsDuffy Fischer$20$14.45 +153.5%Oct 8, 2026
RBC CapitalArun Viswanathan$17$13.91 +115.5%Oct 7, 2026
KeyBancSalvator Tiano$17$13.91 +115.5%Oct 7, 2026
New StreetAnalyst unavailable$17$11.92 +115.5%Oct 5, 2026
OppenheimerKristen Owen$17$11.92 +115.5%Oct 5, 2026
BMO CapitalAnalyst unavailable$15$12.57 +90.1%Oct 2, 2026
Morgan StanleyAnalyst unavailable$18$12.57 +128.1%Oct 2, 2026
OppenheimerKristen Owen$95$80.45 +1104.1%Sep 24, 2026
BMO CapitalJoel Jackson$95$83.11 +1104.1%Sep 16, 2026
New StreetAnalyst unavailable$95$83.39 +1104.1%Sep 16, 2026
UBSAnalyst unavailable$90$83.39 +1040.7%Sep 16, 2026
Deutsche BankDavid Begleiter$101$77.75 +1180.1%Aug 3, 2026
BMO CapitalJoel Jackson$100$78.71 +1167.4%Aug 3, 2026
RBC CapitalArun Viswanathan$103$86.78 +1205.4%Jul 21, 2026
Mizuho SecuritiesAnalyst unavailable$97$85.72 +1129.4%Jul 14, 2026
Mizuho SecuritiesAnalyst unavailable$96$85.25 +1116.7%Jul 2, 2026
BarclaysBenjamin Theurer$91$74.46 +1053.4%Jun 11, 2026
UBSJoshua Spector$86$75.86 +990.0%Jun 9, 2026
Morgan StanleyVincent Andrews$95$79.89 +1104.1%May 28, 2026
RBC CapitalArun Viswanathan$95$78.62 +1104.1%Apr 24, 2026
Wells FargoAnalyst unavailable$90$80.29 +1040.7%Apr 21, 2026
UBSAnalyst unavailable$88$83.56 +1015.3%Apr 9, 2026
Mizuho SecuritiesAnalyst unavailable$82$75.03 +939.3%Feb 17, 2026
UBSJoshua Spector$80$72.6 +913.9%Feb 9, 2026
RBC CapitalAnalyst unavailable$89$72.99 +1028.0%Feb 5, 2026
OppenheimerAnalyst unavailable$86$72.99 +990.0%Feb 5, 2026
Goldman SachsAnalyst unavailable$88$75.12 +1015.3%Feb 5, 2026
Wells FargoAnalyst unavailable$85$75.12 +977.3%Feb 5, 2026
OppenheimerAnalyst unavailable$78$72.63 +888.6%Jan 27, 2026
Mizuho SecuritiesEdlain Rodriguez$80$70.5 +913.9%Jan 16, 2026
OppenheimerAnalyst unavailable$76$63.38 +863.2%Nov 7, 2025
UBSAnalyst unavailable$81$61.53 +926.6%Oct 30, 2025
OppenheimerAnalyst unavailable$75$62.79 +850.6%Oct 22, 2025
Wells FargoAnalyst unavailable$80$61.91 +913.9%Oct 16, 2025
Mizuho SecuritiesAnalyst unavailable$78$65.61 +888.6%Oct 8, 2025
UBSAnalyst unavailable$85$64.56 +977.3%Oct 6, 2025
Morgan StanleyAnalyst unavailable$84$74.29 +964.6%Sep 15, 2025
BMO CapitalAnalyst unavailable$86$74.29 +990.0%Sep 15, 2025
OppenheimerKristen Owen$87$72.09 +1002.7%Jul 15, 2025
KeyBancAleksey Yefremov$71$60.29 +799.9%Apr 14, 2025
KeyBancAleksey Yefremov$69$60.76 +774.5%Nov 21, 2024
CitigroupPatrick Cunningham$68$59.12 +761.9%Oct 23, 2024
Bank of America SecuritiesSteve Byrne$67$57.3 +749.2%Oct 16, 2024
Mizuho SecuritiesJohn Roberts$61$57.85 +673.1%Sep 25, 2024
OppenheimerKriten Owen$69$57.04 +774.5%Sep 17, 2024
KeyBancAleksey Yefremov$62$53 +685.8%Aug 2, 2024
Mizuho SecuritiesJohn Roberts$60$51.89 +660.5%Jun 18, 2024
Wolfe ResearchChris Parkinson$68$51.9 +761.9%Jun 11, 2024
Deutsche BankDavid Begleiter$65$57.03 +723.8%May 6, 2024
RBC CapitalArun Viswanathan$64$57.16 +711.2%May 6, 2024
Canaccord GenuityBobby Burleson$65$56.98 +723.8%May 3, 2024
BMO CapitalJoel Jackson$67$56.98 +749.2%May 3, 2024
JefferiesLaurence Alexander$67$57 +749.2%Mar 28, 2024
Loop Capital MarketsChristopher Kapsch$65$55.04 +723.8%Feb 12, 2024
BNP ParibasLaurent Favre$53$53.04 +571.7%Feb 2, 2024
Wells FargoAnalyst unavailable$77$61.54 +875.9%Feb 3, 2023
CitigroupAnalyst unavailable$74$61.68 +837.9%Feb 3, 2023
Morgan StanleyAnalyst unavailable$80$62.12 +913.9%Jan 11, 2023
BarclaysAnalyst unavailable$75$65.35 +850.6%Nov 17, 2022
UBSAnalyst unavailable$73$66.72 +825.2%Nov 16, 2022
Credit SuisseJohn Roberts$68$51.26 +761.9%Jul 14, 2022
BarclaysBenjamin Theurer$71$53.22 +799.9%Jun 20, 2022
Deutsche BankDavid Begleiter$72$62.04 +812.5%Jun 6, 2022
Argus ResearchBill Selesky$69$60.91 +774.5%May 24, 2022
Mizuho SecuritiesAnalyst unavailable$67$57.99 +749.2%Apr 29, 2022
Roth CapitalBrian White$56$50.25 +609.8%Feb 4, 2022
BarclaysDuffy Fischer$54$47.33 +584.4%Nov 5, 2021
Deutsche BankDavid Begleiter$55$44.79 +597.1%Aug 8, 2021
Argus ResearchBill Selesky$54$45.82 +584.4%May 17, 2021
Bank of America SecuritiesSteve Byrne$42$46.45 +432.3%May 10, 2021
Show less

Track every rating change on CTVA the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Corteva, Inc. operates in the agriculture business. The company operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability.…

Historical context

All CTVA earnings

Basic Materials peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the CTVA recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-11-12T20:09:33.920220+00:00
  2. FN2 earnings calendar · 2026-11-12T01:23:14.140288+00:00
  3. Polygon adjusted daily market bars · 2026-11-12T20:10:45.634456+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-12T20:10:45.631768+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-12. For educational purposes only; not investment advice.